Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Mark Welnick

Diagnostic Radiology Green Bay, WI Medical Doctor

NPI 1255698221 CMS profile 2788866

744 S Webster Ave, Green Bay, WI 54301

Open in the dashboard

General payments

$40,975

163 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Mark Welnick of Green Bay, WI is reported in the CMS Open Payments database as having received $40,975 across 163 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 97th percentile of Diagnostic Radiology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $7,279 21
2024 General $8,397 30
2023 General $12,941 46
2022 General $10,221 33
2021 General $395 8
2020 General $1,023 12
2019 General $719 13

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Mark Welnick
  • Diagnostic Radiology median
  • Middle half of Diagnostic Radiology
  • National median

In program year 2025, general payments to Mark Welnick were reported at $7,279. Among 8,325 Diagnostic Radiology profiles paid that year, the median was $112 and the middle half received between $32 and $349.

Show as a table
Year Mark Welnick Diagnostic Radiology median Middle half National median
2019 $719 $108 $29–$318 $163
2020 $1,023 $65 $21–$252 $114
2021 $395 $92 $24–$292 $132
2022 $10,221 $104 $29–$294 $149
2023 $12,941 $110 $29–$337 $160
2024 $8,397 $113 $30–$356 $164
2025 $7,279 $112 $32–$349 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Penumbra, Inc. $23,048 61 payments
  2. Inari Medical, Inc. $15,468 55 payments
  3. W. L. Gore & Associates, Inc. $1,239 15 payments
  4. Boston Scientific Corporation $552 10 payments
  5. Shockwave Medical, Inc $213 3 payments
  6. Stryker Corporation $113 2 payments
  7. Bard Peripheral Vascular, Inc. $87 3 payments
  8. Surmodics, Inc. $78 4 payments
  9. Medtronic, Inc. $45 3 payments
  10. ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) $32 2 payments
  11. Other $101 5 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $15,675 5 payments
  2. Travel and Lodging $10,748 20 payments
  3. Food and Beverage $8,552 135 payments
  4. Consulting Fee $6,000 3 payments
Products named General payments · program years 2019–2025
  1. Indigo System $19,642 33 payments
  2. FLOWTRIEVER CATHETER, S $15,552 56 payments
  3. CT THROMBECTOMY SYSTEM KIT $15,384 54 payments
  4. Penumbra Coil 400 $1,504 3 payments
  5. Indigo $881 14 payments
  6. Ruby $743 6 payments
  7. GORE VIABAHN VBX Balloon Expandable Endo $646 8 payments
  8. VIABAHN VBX Balloon Expandable Endoprosthesis $446 3 payments
  9. Penumbra System $375 6 payments
  10. TheraSphere Y90 Glass Microspheres 10 GBq $259 3 payments
  11. Other $1,777 53 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 2 drugs

Part D claims

64

Median for Diagnostic Radiology: 24

Drug cost

$675

Median for Diagnostic Radiology: $190

Branded share of claims

67.2%

Median for Diagnostic Radiology: 0%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Clopidogrel Clopidogrel Bisulfate Brand 43 $481
Cilostazol Generic 21 $194

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 1,198 Part D prescribers listed as Diagnostic Radiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 151 billing codes

Paid by Medicare

$77,506

Of which drugs: $2,637

Medicare patients

607

Average age 73

Services billed

1,688

280 women, 327 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 47%
Ischemic heart disease 39%
Chronic kidney disease 31%
Diabetes 30%
Depression 29%
Heart failure 27%
Atrial fibrillation 26%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, gadopiclenol, 1 ml A9573 Office 46 357 $2,476

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

163 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Diagnostic Radiology in Wisconsin

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record